These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 30680529)

  • 1. Examining pharmacodynamic and pharmacokinetic properties of eleven analogues of saquinavir for HIV protease inhibition.
    Jayaswal A; Mishra H; Mishra A; Shah K
    Arch Virol; 2019 Apr; 164(4):949-960. PubMed ID: 30680529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of binding of potential ADMET/tox screened saquinavir analogues for inhibition of HIV-protease via molecular dynamics and binding free energy calculations.
    Jayaswal A; Pathak E; Mishra H; Shah K
    J Biomol Struct Dyn; 2022 Sep; 40(14):6439-6449. PubMed ID: 33663345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.
    Goldfarb NE; Ohanessian M; Biswas S; McGee TD; Mahon BP; Ostrov DA; Garcia J; Tang Y; McKenna R; Roitberg A; Dunn BM
    Biochemistry; 2015 Jan; 54(2):422-33. PubMed ID: 25513833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
    Hong L; Zhang XC; Hartsuck JA; Tang J
    Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
    Prashar V; Bihani SC; Ferrer JL; Hosur MV
    Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux.
    Jain R; Agarwal S; Mandava NK; Sheng Y; Mitra AK
    Int J Pharm; 2008 Oct; 362(1-2):44-51. PubMed ID: 18620036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
    Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of saquinavir in antiretroviral treatment of adult HIV-1 infection in 2001].
    Léautez S; Billaud E
    Presse Med; 2001 Sep; 30(26):1299-303. PubMed ID: 11603093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L; de Mendoza C; Soriano V
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
    HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation.
    He Y; Xia DN; Li QX; Tao JS; Gan Y; Wang C
    Acta Pharmacol Sin; 2015 Sep; 36(9):1151-60. PubMed ID: 26256404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
    Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
    Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.
    Jain R; Duvvuri S; Kansara V; Mandava NK; Mitra AK
    Int J Pharm; 2007 May; 336(2):233-40. PubMed ID: 17207946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Marcelin AG; Dalban C; Peytavin G; Lamotte C; Agher R; Delaugerre C; Wirden M; Conan F; Dantin S; Katlama C; Costagliola D; Calvez V
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4687-92. PubMed ID: 15561845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
    Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
    Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal in situ gel loaded with saquinavir mesylate nanosized microemulsion: preparation, characterization, and in vivo evaluation.
    Hosny KM; Hassan AH
    Int J Pharm; 2014 Nov; 475(1-2):191-7. PubMed ID: 25178831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
    Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
    Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
    Churchill DR; Pym AS; Galpin S; Foxall R; Stainsby C; Clarke JR; Kaye S; Bloor S; Larder BA; Wills B; Sun E; Babiker AG; Back DJ; Weber JN
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1181-9. PubMed ID: 10480631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.